Dr. Tracey L McLaughlin, MD
Claim this profileStanford University
Affiliated Hospitals
Stanford University
Stanford Health
Clinical Trials Tracey L McLaughlin, MD is currently running
Dietary Interventions
for Insulin Resistance
This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR). Blood, adipose and stool are sampled at three timepoints; baseline, peak weight (4 weeks) and post weight loss to monitor changes in cellular processes. Additionally, direct insulin sensitivity testing, and radiological measurement of visceral fat and intrahepatic fat content is measured at three timepoints to correlate clinical indices with cellular changes.
Recruiting
1 award
N/A
4 criteria
Tirzepatide
for Obesity
Obesity, affecting 40% of US adults and costing 173b annually, represents a significant health care burden (1). It is associated with increased risk for multiple chronic diseases including hypertension, type 2 diabetes (T2D), cardiovascular disease, and NAFLD, as well as cancer, osteoarthritis, and obstructive sleep apnea. The investigators plan to test the hypothesis that tirzepatide, a dual GLP/GIP agonist, improves metabolic health (insulin resistance and regional fat distribution and cardiovascular risk profile) not only by inducing weight loss via GLP1-agonism, but also via beneficial cellular and molecular changes in adipose tissue, given that GIP binds receptors in human fat cells. Based on studies in mice showing that GIP alone or tirzepitide treatment decreases inflammation, increases lipid buffering (fat storage in the fat cells instead of releasing it into the bloodstream), and improves glucose homeostasis. The investigators believe that the GIP component of tirzepatide will make fat cells healthier and reverse lipotoxicity, which is one of the mechanisms by which obesity leads to insulin resistance, disordered regional fat distribution, and type 2 diabetes. To date, the effect of dual GLP1 and GIP agonist treatment on adipose tissue has not been evaluated in humans. Given the existing but limited data, dual GIP/GLP-1 agonist treatment in obese humans with metabolic risk factors is an attractive pharmacologic candidate that would lead to both weight loss and healthier fat, potentially offering uniquely powerful synergistic clinical benefits. It is thus of tremendous importance to define the biological effects of dual-agonist treatment on human adipose tissue structure and function, as well as related improvements in regional fat distribution and systemic adipose and muscle insulin sensitivity. In this study, the investigators will randomize overweight (with risk factors) or obese nondiabetic individuals to hypocaloric diet or tirzepatide for 22 weeks with matched weight loss for the first 6 weeks. The investigators will quantify insulin resistance, fat and lean mass, including regional fat distribution, and changes in adipose tissue (needle biopsy from abdominal fat tissue) to see if tirzepatide effects differ from dietary weight loss.
Recruiting
1 award
Phase 2
2 criteria
More about Tracey L McLaughlin, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Tracey L McLaughlin, MD has experience with
- GLP-1A
- Mediterranean Diet
- Metformin
- Use Of Cardea Solo Monitoring
- Use Of Continuous Glucose Monitor (CGM)
- Precision Diets
Breakdown of trials Tracey L McLaughlin, MD has run
Type 2 Diabetes
Insulin Resistance
Obesity
Incretin Hormones in Polycystic Ovary Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tracey L McLaughlin, MD specialize in?
Tracey L McLaughlin, MD focuses on Type 2 Diabetes and Insulin Resistance. In particular, much of their work with Type 2 Diabetes has involved treating patients, or patients who are undergoing treatment.
Is Tracey L McLaughlin, MD currently recruiting for clinical trials?
Yes, Tracey L McLaughlin, MD is currently recruiting for 4 clinical trials in Stanford California. If you're interested in participating, you should apply.
Are there any treatments that Tracey L McLaughlin, MD has studied deeply?
Yes, Tracey L McLaughlin, MD has studied treatments such as GLP-1A, Mediterranean Diet, Metformin.
What is the best way to schedule an appointment with Tracey L McLaughlin, MD?
Apply for one of the trials that Tracey L McLaughlin, MD is conducting.
What is the office address of Tracey L McLaughlin, MD?
The office of Tracey L McLaughlin, MD is located at: Stanford University, Stanford, California 94305 United States. This is the address for their practice at the Stanford University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.